

AXIRON NET SALES, QUARTER TO 31 MARCH 2016

Acrux (ASX: ACR) today confirmed that Eli Lilly and Company reported global Axiron net sales of US\$37.0 million in its financial results for the quarter ending 31 March 2016, compared to US\$39.1 million for the prior corresponding quarter to 31 March, 2015.

Axiron net sales for the previous corresponding quarters are shown in the following table:

Q1 2015	Q2 2015	Q3 2015	Q4 2015
US\$39.1m	US\$32.4m	US\$41.4m	US\$41.6m
Q1 2016			
US\$37.0m			

For further information, contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

About Acrux

Acrux (ASX: ACR) is a drug development company focused on commercialising topical products using its proprietary drug delivery technology. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and licensed a number of pharmaceutical products in the US and Europe using the Patchless Patch™, a fast-drying and invisible topical application technology. Acrux will continue to innovate and bring its developed products to the market in collaboration with licensees.

For further information on Acrux, visit www.acrux.com.au

